Table 3.

Change from baseline variables in patients with refractory severe asthma with the eosinophilic–allergic phenotype, week-52 after mepolizumab by blood eosinophil count (cells μL) -<600 (n = 42) vs. ≥600 (n = 19)- categories.

Variables	Baseline	After 52-Weeks of Mepolizumab	p
ACT * (<600)	12.38 ± 4.66	18.03 ± 5.27	<0.0001
ACT * (≥600)	14.63 ± 4.19	20.41 ± 3.43	<0.0001
Annual AEs * (<600)	3.33 ± 1.49	1.06 ± 1.38	<0.0001
Annual AEs * (≥600)	3.47 ± 0.96	0.8 ± 0.73	<0.0001
FEV1 * (<600)	2236.19 ± 764.3	2400.64 ± 730.59	0.002
FEV1 * (≥600)	2387.36 ± 622	2933.76 ± 476.09	0.0002
FENO (<600)	47.6 ± 20.81	41.42 ± 28.75	0.4
FENO (≥600)	67.75 ± 53.72	79.21 ± 60.88	0.84

ACT: Asthma Control Test. AEs: Asthma exacerbations. FEV1: Forced expiratory volume in the first second shown in mL. FENO: Fractional exhaled nitric oxide shown in ppb. sIgE: Specific IgE. Mean values and standard deviation are shown. (*) Indicates statistical significance (p < 0.05).